The expression of multiple immune cells (CD8, Foxp3, CD68, CD163, CD20, CD11c, CD66b, CD56, PD-L1, INF-γ, Ki67 and VEGFR-2) in the tumor center (TC), tumor invasive front (< 150 μm from the tumor center, TF) and peritumoral region (≥ 150 μm from the tumor center, PT) was evaluated via comparison. This evidence concerns the gene ITGAX and neoplasm.